Alumis Inc. (ALMS)
$6.56-7.08%Close
SELLCRISIS · day 45
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $810M
- Beta
- -0.67
- P/E (TTM)
- -1.73
- Short % float
- 11.99%
- Days to cover
- 3.6
- SI change
- +63.5%
- 1W
- -5.34%
- 1M
- -28.85%
- vs SPY 1W
- -5.20%
- vs SPY 1M
- -31.36%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 1
- VALUE
- 3
- GROWTH
- 19
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-61.8%
REV YoY-
ROE-103.0%
EPS YoY-
ROA-78.3%
GROSS88
OP-6204
NET-5933
[VALUATION]
P/E TTM-1.73
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.85
P/FCF-
EV/EBITDA-1.77
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E8.06
ALTMAN Z-
CURR RATIO6.74
ND/EBITDA-
BETA-0.67
Company news
FAQ
- What is LOPJLB’s current signal on ALMS?
- LOPJLB’s latest quantitative signal on Alumis Inc. (ALMS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ALMS in?
- Alumis Inc. (ALMS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Alumis Inc. (ALMS) do?
- Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment…